PHILADELPHIA — (Jan. 12, 2021) — Scientists at The Wistar Institute have created an advanced humanized immune system mouse model that allows them to examine resistance to immune checkpoint blockade therapies in melanoma. It has revealed a central role for mast cells. These findings were published today in the journal Nature Communications.
Checkpoint inhibitors revolutionized therapeutic options for advanced melanoma. However, only a fraction of patients respond to this treatment and some relapse due to reemergence of therapy-resistant lesions.
“To better understand why some cancers do not respond or become resistant to checkpoint therapies, we need more preclinical models that mimic the human tumor immune environment,” said Rajasekharan Somasundaram, Ph.D., a member of The Wistar Institute Melanoma Research Center, who is the first and corresponding author of the paper.
Due to critical differences in the murine and human immune systems, mouse models do not allow the study of immune mechanisms that are uniquely human. “Humanized” mouse models are widely used to mimic the human immune system in mice.
Wistar’s new humanized mouse model relies upon transplanted human stem cells and tissues that have been uniquely engineered to produce combinations of human cytokines that result in a more physiologically relevant model system for evaluating new immuno-oncology therapies and effective treatments targeting the tumor microenvironment.
“Our novel humanized mouse model has a longer life span and allowed us to study treatment responses to immunotherapies after human tumor transplant,” said Somasundaram, who was part of a Wistar team led by Meenhard Herlyn, D.V.M., D.Sc., professor in The Wistar Institute Cancer Center, director of The Wistar Institute Melanoma Research Center, and a co-senior author on the study.
Researchers transplanted human metastatic melanoma cell lines into their humanized mouse model and treated them with anti-PD-1 antibody therapy. By studying immune cell infiltration into the tumors, Somasundaram and colleagues observed an abundance of infiltrated mast cells in anti-PD-1-treated tumors. Mast cells are an immune cell found throughout the body, especially in the skin and mucosa, where they serve as a first line of defense against pathogens. In samples from melanoma patients receiving immune checkpoint therapies, the team saw the same higher abundance of mast cells in non-responding tumors.
The authors showed that combining anti-PD-1 therapy with small molecule inhibitors able to deplete mast cells caused complete regression of tumors in mice and prolonged survival in comparison with mice receiving either treatment. Importantly, mice that reached remission did not show any signs of recurrence for four weeks after cessation of therapy and developed memory T cell response against melanoma tumors.
“Our results suggest that mast cells are associated with resistance to anti-PD-1 therapy, and that depleting mast cells is beneficial to immune checkpoint therapy responses,” said Herlyn. “This warrants further investigation into the development of new combined immunotherapy approaches with small molecule inhibitors for the treatment of melanoma patients.”
Co-authors: Thomas Connelly, Robin Choi, Hyeree Choi, Anastasia Samarkina, Ling Li, Elizabeth Gregorio, Yeqing Chen, Mohamed Abdel-Mohsen, Marilda Beqiri, Meaghan Kiernan, Michela Perego, Fang Wang, Min Xiao, Denitsa Hristova, Joshua Wang, Mizuho Fukunaga-Kalabis, Clemens Krepler, Fang Ping-Chen, Xiang Y. Zhou, Alexis Gutierrez, Frederick Keeney, James Hayden, Brian J. Gavin, David Weiner, Luis J. Montaner, Qin Liu, and Dmitry Gabrilovich (now at AstraZeneca) from Wistar; Rohit Thakur, Elizabeth M. Burton, Michael A. Davies, Michael T. Tetzlaff, and Jennifer A. Wargo from MD Anderson Cancer Center, Houston, Texas; Xiaowei Xu, Alex Huang, Anthony Secreto, Gwenn Danet-Desnoyers, Daniel Traum, Klaus H. Kaestner, and Alex Huang from University of Pennsylvania; Johannes Griss from Medical University of Vienna, Vienna, Austria; Lukas Peiffer and Ju?rgen Becker from University of Duisburg-Essen, Essen, Germany.
Work supported by: National Institutes of Health (NIH) grants P50 CA174523 and U54 CA224070; Department of Defense Peer Reviewed Cancer Research Program grants WX1XWH-16-1-0119 (CA150619), W81XWH-16-1-0120 and W81XWH-16-1-0121; Additional support was provided by the University of Texas MD Anderson Cancer Center Melanoma Moon shot Program and the Dr. Miriam and Sheldon G. Adelson Medical Research Foundation. Support for The Wistar Institute facilities was provided by Cancer Center Support Grant P30 CA010815.
Publication information: “Tumor-infiltrating mast cells are associated with therapy resistance to anti-PD-1”, Nature Communications (2020). Online publication.
The Wistar Institute is an international leader in biomedical research with special expertise in cancer research and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. wistar.org.